Positive outcome with significant efficacy • 25%

Mixed outcome with limited efficacy • 25%

Negative outcome with no efficacy • 25%

Trial terminated early due to safety concerns • 25%

Complete Response • 25%

Partial Response • 25%

Stable Disease • 25%

Progressive Disease • 25%

Complete Response (CR) • 25%

Partial Response (PR) • 25%

Stable Disease (SD) • 25%

Progressive Disease (PD) • 25%

Completed with positive results • 25%

Completed with negative results • 25%

Not completed • 25%

Unknown/Other • 25%

Positive efficacy and safety results • 25%

Positive efficacy, but safety concerns • 25%

Negative efficacy, but good safety • 25%

Negative efficacy and safety concerns • 25%

Significant improvement • 25%

Moderate improvement • 25%

No improvement • 25%

Worsening condition • 25%

Yes • 50%

No • 50%

Yes • 50%

No • 50%

Successful with no major adverse effects • 25%

Successful with minor adverse effects • 25%

Unsuccessful due to lack of efficacy • 25%

Unsuccessful due to major adverse effects • 25%

Primary endpoint met with significant improvement • 25%

Primary endpoint met with moderate improvement • 25%

Primary endpoint not met • 25%

Trial inconclusive or delayed • 25%

Meets primary endpoint • 25%

Fails primary endpoint • 25%

Mixed results • 25%

Trial not completed by end of 2025 • 25%

Positive results for B-cell malignancies • 25%

Positive results for autoimmune diseases • 25%

Negative results for both • 25%

Mixed results • 25%